Johnson & Johnson $JNJ Shares Sold by Chapin Davis Inc.

Chapin Davis Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,860 shares of the company’s stock after selling 2,924 shares during the period. Johnson & Johnson comprises 1.2% of Chapin Davis Inc.’s portfolio, making the stock its 24th largest holding. Chapin Davis Inc.’s holdings in Johnson & Johnson were worth $6,568,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of JNJ. Fermata Advisors LLC boosted its position in shares of Johnson & Johnson by 1.8% in the 2nd quarter. Fermata Advisors LLC now owns 5,388 shares of the company’s stock worth $1,368,000 after buying an additional 95 shares in the last quarter. 180 Wealth Advisors LLC boosted its position in Johnson & Johnson by 4.4% during the second quarter. 180 Wealth Advisors LLC now owns 12,751 shares of the company’s stock worth $3,238,000 after acquiring an additional 538 shares during the last quarter. First Citizens Financial Corp boosted its holdings in shares of Johnson & Johnson by 1.0% during the second quarter. First Citizens Financial Corp now owns 7,380 shares of the company’s stock worth $1,874,000 after purchasing an additional 70 shares during the last quarter. Foster Group Inc. boosted its stake in Johnson & Johnson by 1.3% in the 2nd quarter. Foster Group Inc. now owns 5,808 shares of the company’s stock worth $1,475,000 after buying an additional 77 shares during the last quarter. Finally, Mirador Capital Partners LP grew its holdings in Johnson & Johnson by 4.2% in the second quarter. Mirador Capital Partners LP now owns 7,410 shares of the company’s stock valued at $1,882,000 after purchasing an additional 302 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Guggenheim reaffirmed a “buy” rating and set a $270.00 price target on shares of Johnson & Johnson in a report on Friday, July 17th. Argus set a $300.00 price objective on Johnson & Johnson in a research note on Wednesday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Finally, Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $267.48.

Johnson & Johnson Price Performance

Shares of JNJ opened at $257.77 on Thursday. Johnson & Johnson has a one year low of $169.68 and a one year high of $274.90. The firm has a market capitalization of $621.21 billion, a price-to-earnings ratio of 29.87, a price-to-earnings-growth ratio of 2.42 and a beta of 0.24. The stock’s fifty day moving average is $247.27 and its 200-day moving average is $239.32. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.69 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is 62.11%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA clearance expands J&J’s growth opportunities. The FDA authorized Johnson & Johnson’s OTTAVA robotic surgery system, marking the company’s entry into surgical robotics. Investors may view the platform as a long-term medical-device growth driver and a way to diversify beyond pharmaceuticals. Johnson & Johnson Gets FDA Nod for OTTAVA
• Positive Sentiment: Analysts continue to support JNJ’s outlook. Wells Fargo reportedly expects the stock to rise, while other market commentary identifies Johnson & Johnson as an attractive blue-chip and dependable dividend stock. The company’s latest quarter also showed earnings and revenue exceeding estimates, with full-year 2026 earnings guidance maintained at $11.60-$11.75 per share. Wells Fargo Analyst Expects Johnson & Johnson Stock to Rise
• Positive Sentiment: Dividend appeal is supporting defensive demand. JNJ is being highlighted alongside other Dividend Aristocrats for dependable income. Its large scale, 21.48% net margin, 32.42% return on equity and low-beta profile may appeal to investors seeking stability while broader equity valuations remain elevated. Strong Buy Dividend Aristocrat Stocks
• Neutral Sentiment: Leadership transition adds a near-term watchpoint. Innovative Medicine chairman Jennifer Taubert will retire after more than two decades at J&J, with Tom Cavanaugh set to succeed her in September. Taubert helped build the segment into a business generating more than $60 billion in annual revenue, making execution under the new leader important for investors. Johnson & Johnson Leadership Change

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.